PMID- 15899913
OWN - NLM
STAT- MEDLINE
DCOM- 20050929
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 106
IP  - 5
DP  - 2005 Sep 1
TI  - Efficient migration of dendritic cells toward lymph node chemokines and induction 
      of T(H)1 responses require maturation stimulus and apoptotic cell interaction.
PG  - 1734-41
AB  - Dendritic cells (DCs) have the unique ability to initiate primary immune 
      responses, and they can be conditioned for vaccinal purposes to present antigens 
      after the engulfment of apoptotic cells. To recruit the rare antigen-specific 
      naive T cells, DCs require a maturation step and subsequent transport toward 
      lymph node (LN). To date, prostaglandin E2 (PGE2) is the best-characterized 
      compound inducing this LN-directed migration in vitro, but PGE2 may skew the 
      immune responses in a T(H)2 direction. We demonstrate here that on incubation 
      with apoptotic tumor cells and tumor necrosis factor-alpha (TNF-alpha) or 
      lipopolysaccharide (LPS), human monocyte-derived DCs become fully mature and 
      acquire high migratory capacities toward LN-directing chemokines. The migration 
      of TNF-alpha-treated DCs occurs only after cotreatment with apoptotic cells but 
      not with necrotic cells. DC migration requires CD36 expression and incubation 
      with apoptotic cells in the presence of heat-labile serum components. Moreover, 
      on treatment with apoptotic cells and LPS, the migrating DCs are able to recruit 
      naive T cells to generate T(H)1 immune responses. Our results show that the 
      cotreatment of DCs with apoptotic tumor cells and inflammatory signals is 
      promising for the design of an antitumoral DC-based vaccine.
FAU - Bertho, Nicolas
AU  - Bertho N
AD  - Immunology Department, UMR8115 Genethon BP60, 1 bis rue de l'Internationale, 
      91002 Evry Cedex, France. bertho@genethon.fr
FAU - Adamski, Henri
AU  - Adamski H
FAU - Toujas, Louis
AU  - Toujas L
FAU - Debove, Martine
AU  - Debove M
FAU - Davoust, Jean
AU  - Davoust J
FAU - Quillien, Veronique
AU  - Quillien V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050517
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Apolipoproteins C)
RN  - 0 (Chemokines, CC)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Apolipoproteins C/pharmacology
MH  - Apoptosis/*immunology
MH  - Cell Communication/immunology
MH  - Cell Differentiation/immunology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects/*immunology
MH  - Cell Polarity/drug effects/immunology
MH  - Chemokines, CC/*immunology/pharmacology
MH  - Dendritic Cells/drug effects/*immunology
MH  - Dinoprostone/pharmacology
MH  - Humans
MH  - Lipopolysaccharides/pharmacology
MH  - Lymph Nodes/cytology/*immunology
MH  - Phenotype
MH  - Structure-Activity Relationship
MH  - T-Lymphocytes/drug effects/immunology
MH  - Th1 Cells/*immunology
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2005/05/19 09:00
MHDA- 2005/09/30 09:00
CRDT- 2005/05/19 09:00
PHST- 2005/05/19 09:00 [pubmed]
PHST- 2005/09/30 09:00 [medline]
PHST- 2005/05/19 09:00 [entrez]
AID - S0006-4971(20)53081-4 [pii]
AID - 10.1182/blood-2004-10-3991 [doi]
PST - ppublish
SO  - Blood. 2005 Sep 1;106(5):1734-41. doi: 10.1182/blood-2004-10-3991. Epub 2005 May 
      17.